This is crazy - we are post positive results in p2, deal in hand with scope for more from RoW and we have lost value from pre deal - we are lower than pre p2 results if memory serves me correctly.
I don't understand this stock because on fundamentals, for a p3 ready drug, with a seemingly easy (and repeatable) results, we should be multiples of our current price.
I made this point recently on a thread - this seems to be purely a result of the market we trade in. i cant see any reason why we are not climbing in terms of SP. If we were listed in the US I think it would be a different story.
At least that is the only logical conclusion I can come to.
Ann: Plans for Phase 3 trial in Rett syndrome, page-28
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.97 |
Change
1.425(11.4%) |
Mkt cap ! $1.728B | |||
| Open | High | Low | Value | Volume |
| $12.96 | $14.00 | $12.91 | $5.412M | 399.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 403 | $13.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.99 | 720 | 4 |
View Market Depth
| Last trade - 10.54am 26/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |